Clay Siegall is the CEO and chair of Seattle Genetics. He co-founded the medical research company in 1998 and has been with it ever since. Siegall has a Bachelor’s degree in Zoology from the University of Maryland. He received his post-graduate degree in Genetics from George Washington University. He is responsible for making sure that the company meets its objectives and goals as the CEO. Clay Siegall has to align the operations so that the firm is able to achieve growth and sales targets. Siegall is also involved in the fund-raising efforts of the company from both public and private investors. He was instrumental in taking the company public when it raised $670 million from investors in 2001.
Seattle Genetics was able to develop ADCETRIS under his leadership. This is the first anti-cancer therapy to be approved by the FDA. He secured partnerships with other pharmaceutical companies including Progenics, Bayer, and Genentech. He is the director of various pharmaceutical companies such as Mirna Therapeutics, Alder Biopharmaceuticals, and Ultragenyx Pharmaceutical. His decision to pursue a career in the medical field came when he saw the pain that a close family member had to undergo when being treated for cancer. Siegall is still involved in medical research. He has authored more than 50 publications to date. He also holds 15 patents as a result of the innovations that he has developed.
Siegall frequently posts about current issues that are impacting the world on his blog. His recent posts have been on the decision by the US Government to withdraw from the Paris Accord. President Trump said that the pact imposed unfair standards for businesses in the country. Trump stated that this was not right and that he was fighting against the deal by withdrawing the country. He said that he was open to negotiating a better deal that would have better terms for the people of the US. An energy economist discusses the effects that this would have for the country’s energy ecosystem in one of the posts. The economist pointed out that the pact had not been fully implemented. Its effects had not been felt.